A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
"Our findings are concerning, as even people with a mild case of COVID-19 are showing changes in their brains months later. More studies are needed to hopefully identify treatments to prevent any long-term effects on people's quality of life," she added.
What happened to the variants that once wreaked havoc? “For all intents and purposes, we can consider them gone,” said David Dowdy, an epidemiology professor at Johns Hopkins Bloomberg School of Public Health.
In its new variant estimates today, the Centers for Disease Control and Prevention (CDC) said the XBB.1.5 Omicron subvariant is now dominant the northwestern region, making it the most
Also, the more transmissible variant expanded its footprint in areas where it already dominates, and in the United States as a whole, it accounts for an estimated 80.2% of samples, up steadily from 74.7% the previous week.
Recent Comments